Biomarker-guided therapy for colorectal cancer: strength in complexity

A Sveen, S Kopetz, RA Lothe - Nature Reviews Clinical Oncology, 2020 - nature.com
The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …

Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer

SS Fois, P Paliogiannis, A Zinellu, AG Fois… - International journal of …, 2021 - mdpi.com
Lung cancer is the leading cause of death for malignancy worldwide. Its molecular profiling
has enriched our understanding of cancer initiation and progression and has become …

Mutations of key driver genes in colorectal cancer progression and metastasis

D Huang, W Sun, Y Zhou, P Li, F Chen, H Chen… - Cancer and Metastasis …, 2018 - Springer
The association between mutations of key driver genes and colorectal cancer (CRC)
metastasis has been investigated by many studies. However, the results of these studies …

Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review

JH Strickler, T Yoshino, K Stevinson… - The …, 2023 - academic.oup.com
Purpose A systematic literature review was conducted to estimate the global prevalence of
Kirsten rat sarcoma virus gene (KRAS) mutations, with an emphasis on the clinically …

Targeted therapies in cholangiocarcinoma: emerging evidence from clinical trials

MM Simile, P Bagella, G Vidili, A Spanu, R Manetti… - Medicina, 2019 - mdpi.com
Cholangiocarcinoma (CCA) is a highly-aggressive malignancy arising from the biliary tree,
characterized by a steady increase in incidence globally and a high mortality rate. Most …

[PDF][PDF] Frequency of RAS mutations (KRAS, NRAS, HRAS) in human solid cancer

H Kodaz, O Kostek, MB Hacioglu, B Erdogan… - Breast cancer, 2017 - ejmo.org
RAS oncogene affects numerous cellular functions including growth, proliferation, apoptosis,
migration, division and differentiation of the cells. It has 3 known isoforms as Harvey-RAS …

The long-term survival characteristics of a cohort of colorectal cancer patients and baseline variables associated with survival outcomes with or without time-varying …

Y Yu, M Carey, W Pollett, J Green, E Dicks, P Parfrey… - BMC medicine, 2019 - Springer
Background Colorectal cancer is the third most common cancer in the world. In this study,
we assessed the long-term survival characteristics and prognostic associations and …

Timeline of FDA-approved targeted therapy for cholangiocarcinoma

SM Cho, A Esmail, A Raza, S Dacha, M Abdelrahim - Cancers, 2022 - mdpi.com
Simple Summary Cholangiocarcinoma constitutes around 3% of gastrointestinal cancers,
and mortality from this cancer has been rising in the recent decades. Many cases of …

Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report

F El Agy, S El Bardai, I El Otmani, Z Benbrahim… - PLoS …, 2021 - journals.plos.org
This study aimed to estimate the incidence of KRAS, NRAS, and BRAF mutations in the
Moroccan population, and investigate the associations of KRAS and NRAS gene mutations …

Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study

M Casula, P Paliogiannis, F Ayala, V De Giorgi… - BMC cancer, 2019 - Springer
Introduction Multiple primary melanomas (MPM) occur up to 8% of patients with cutaneous
malignant melanoma (CMM). They are often sporadic harbouring several somatic mutations …